ESTRO Brachytherapy for Prostate Cancer 2018

Summary of first presentation

⚫ Long-term morbidity rate is low. (LoE: III)

⚫ Technical advances improve tumor control and lower toxicity.

⚫ Careful patient selection is important to avoid unacceptable morbidity.

⚫ Urgent need for prospective trials to investigate on medical approaches to the treatment of morbidity.